Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

作者：Zijun Wang, Frauke Muecksch, Dennis J. Schaefer-Babajew, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Hans.-Heinrich Hoffmann, Christopher O. Barnes, Melissa Cipolla, Víctor Ramos, Thiago Y. Oliveira, Alice Cho, Fabian Schmidt, Justin Da Silva, Eva Bednarski, Lauren C. Aguado, Jim K. Yee, Mridushi Daga, Martina Turroja, Katrina G. Millard, Mila Janković, Anna Gazumyan, Zhen Zhao, Charles M. Rice, Paul D. Bieniasz, Marina F. Caskey, Théodora Hatziioannou, Michel C. Nussenzweig · 发表于：Nature · 年份：2021 · DOI：10.1038/s41586-021-03696-9 · 被引用次数：806 · 研究领域：SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、vaccines and immunoinformatics approaches

Abstract More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies 1,2 . Here we report on a cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 and 12 months after SARS-CoV-2 infection, 41% of whom also received mRNA vaccines 3,4 . In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable between 6 and 12 months after infection. Vaccination increases all components of the humoral response and, as expected, results in serum neutralizing activities against variants of concern similar to or greater than the neutralizing activity against the original Wuhan Hu-1 strain achieved by vaccination of naive individuals 2,5–8 . The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in the variants of concern 4,9 . In addition, B cell clones expressing broad and potent antibodies are selectively retained in ...